Arrowstreet Capital Limited Partnership Sells 111,794 Shares of HealthEquity, Inc. (NASDAQ:HQY)

Arrowstreet Capital Limited Partnership lowered its position in shares of HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 94.4% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 6,666 shares of the company's stock after selling 111,794 shares during the period. Arrowstreet Capital Limited Partnership's holdings in HealthEquity were worth $640,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of HQY. Pier Capital LLC bought a new stake in shares of HealthEquity during the fourth quarter valued at approximately $8,024,000. HighTower Advisors LLC grew its stake in shares of HealthEquity by 4.8% in the fourth quarter. HighTower Advisors LLC now owns 95,075 shares of the company's stock worth $9,122,000 after purchasing an additional 4,370 shares in the last quarter. Geneva Capital Management LLC increased its holdings in shares of HealthEquity by 24.6% during the fourth quarter. Geneva Capital Management LLC now owns 1,048,903 shares of the company's stock valued at $100,642,000 after purchasing an additional 206,894 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of HealthEquity by 2.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,086,811 shares of the company's stock valued at $104,280,000 after purchasing an additional 25,004 shares in the last quarter. Finally, Venturi Wealth Management LLC acquired a new stake in shares of HealthEquity in the 4th quarter worth approximately $238,000. Institutional investors and hedge funds own 99.55% of the company's stock.

Insider Transactions at HealthEquity

In other news, Director Robert W. Selander sold 5,750 shares of the firm's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $111.29, for a total transaction of $639,917.50. Following the completion of the transaction, the director now owns 78,219 shares of the company's stock, valued at approximately $8,704,992.51. This trade represents a 6.85 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael Henry Fiore sold 8,881 shares of the business's stock in a transaction on Friday, April 4th. The stock was sold at an average price of $78.26, for a total transaction of $695,027.06. Following the completion of the sale, the executive vice president now directly owns 56,655 shares in the company, valued at approximately $4,433,820.30. This represents a 13.55 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 20,381 shares of company stock valued at $1,781,432. 2.20% of the stock is currently owned by insiders.

Remove Ads

HealthEquity Price Performance

NASDAQ:HQY traded down $1.26 during mid-day trading on Wednesday, reaching $81.77. The stock had a trading volume of 316,344 shares, compared to its average volume of 760,068. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.20 and a quick ratio of 3.20. HealthEquity, Inc. has a 12 month low of $65.01 and a 12 month high of $115.59. The stock has a market capitalization of $7.07 billion, a PE ratio of 75.02, a P/E/G ratio of 1.60 and a beta of 0.49. The stock has a 50-day simple moving average of $96.47 and a two-hundred day simple moving average of $96.35.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on HQY. Raymond James raised shares of HealthEquity from an "outperform" rating to a "strong-buy" rating and lowered their price objective for the stock from $120.00 to $115.00 in a research note on Tuesday, March 25th. Wells Fargo & Company raised their price target on HealthEquity from $110.00 to $125.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Barrington Research reiterated an "outperform" rating and set a $112.00 target price on shares of HealthEquity in a research report on Friday, April 11th. KeyCorp dropped their target price on shares of HealthEquity from $110.00 to $100.00 and set an "overweight" rating for the company in a research note on Wednesday. Finally, The Goldman Sachs Group cut their price target on shares of HealthEquity from $107.00 to $94.00 and set a "neutral" rating on the stock in a research report on Thursday, March 27th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $111.75.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.